目錄:MedChemExpress LLC>>信號通路>> LV-320 | MCE
CAS | 2449093-46-1 | 分子量 | 520.11 |
---|---|---|---|
分子式 | C??H??ClNO?S? | 供貨周期 | 現(xiàn)貨 |
規(guī)格 | 5 mg | 貨號 | HY-112711 |
應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報,我們不為任何個人用途提供產(chǎn)品和服務(wù)。
產(chǎn)品活性:LV-320 是一種有效且非競爭性的 ATG4B 抑制劑,其 IC50 值為 24.5 μM,Kd 值為 16 μM。 LV-320 抑制 ATG4B 的酶促活性,阻斷細(xì)胞自噬,并且在體內(nèi)穩(wěn)定,無毒且有活性。
研究領(lǐng)域:Autophagy | Metabolic Enzyme/Protease
作用靶點:Autophagy | Cathepsin
In Vitro: LV-320 (0-120?µM; SKBR3, MCF7, JIMT1, and MDA-MB-231 cells) treatment results in a dose-dependent increase in endogenous LC3B-II and protein p62 levels in all four cell lines.
LV-320 (120?µM; 48 hours; MDA-MB-231 cells) treatment results in an increase in LC3B-II, indicating that LV-320 blocks autophagic flux.
In Vivo: LV-320 (100-200?mg/kg; oral gavage; three times over two days; GFP-LC3 mice) treatment results in a terminal blood level of 169 µM and a liver level of 104 µM. The expression of GFP-LC3 puncta is significantly greater accumulation in LV-320 treated animals compared to controls. LC3B-II protein is also increased in LV-320-treated animals. The treatment do not cause significant toxicity in mice at either dose.
相關(guān)產(chǎn)品:Bioactive Compound Library Plus | Metabolism/Protease Compound Library | Anti-Cancer Compound Library | Autophagy Compound Library | Angiogenesis-Related Compound Library | Targeted Diversity Library | Membrane Protein-targeted Compound Library | Cathepsin X-IN-1 | RO5461111 | Balicatib | MK-0674 | Cathepsin D and E FRET Substrate acetate | L-006235 | CA-074 methyl ester | Ac-Leu-Val-Lys-Aldehyde | Papain | VBY-825 | Cathepsin inhibitor 1 | Z-Arg-Arg-4MβNA triacetate | L-873724 | Cathepsin C-IN-4 | Cathepsin C-IN-3 | Odanacatib | N-CBZ-Phe-Arg-AMC | Cysteine Protease inhibitor | Z-FA-FMK | Relacatib | E-64 | 2-Cyanopyrimidine | Cathepsin C-IN-5 | ALLM | Z-LVG-CHN2 | SID 26681509 quarterhydrate | Gü1303 | Z-WEHD-FMK | GSK-2793660 free base | TSC25
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫,我們致力于為全球科研客戶提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng);
• 產(chǎn)品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產(chǎn)品,廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學(xué)分析檢測分析,藥物篩選等專業(yè)技術(shù)服務(wù);
• 設(shè)有專業(yè)的實驗中心和嚴(yán)格的質(zhì)控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告,確保產(chǎn)品的高純度、高品質(zhì);
• 產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團(tuán)隊跟蹤最新的制藥及生命科學(xué)研究進(jìn)展,為您提供全球新的活性化合物;
• 與世界各大制藥公司及著名科研機構(gòu)建立了長期的合作。
(空格分隔,最多3個,單個標(biāo)簽最多10個字符)